Search results for Zalifrelimab

Zalifrelimab Biosimilar – Anti-CTLA4, CD152 mAb – Research Grade, ProteoGenix, PX-TA1559

Description of Zalifrelimab Biosimilar - Anti-CTLA4, CD152 mAb - Research Grade Introduction Zalifrelimab Biosimilar, also known as Anti-CTLA4 or CD152 monoclonal antibody, is a research grade therapeutic antibody that has been developed as a potential treatment for various types of cancer. This biosimilar is designed to mimic the activity of the original antibody, Ipilimumab, which has been approved by the FDA for the treatment of melanoma. In this article, we will explore the structure, activity, and potential applications of Zalifrelimab Biosimilar. Structure of Zalifrelimab Biosimilar Zalifrelimab Biosimilar is a recombinant monoclonal antibody that is produced in a laboratory using recombinant DNA technology. It is composed of two identical heavy chains and two identical light chains, each containing a variable region and a constant region. The variable regions of the antibody are responsible for binding to its target, while the constant regions provide stability and effector functions. The structure of Zalifrelimab Biosimilar is very similar to that of the original antibody, Ipilimumab. Both antibodies are of the IgG1 isotype and have a similar overall shape. However, Zalifrelimab Biosimilar has been engineered to have a higher binding affinity for its target, making it potentially more effective in treating cancer. Activity of Zalifrelimab Biosimilar Zalifrelimab Biosimilar works by targeting a protein called CTLA-4, which is found on the surface of certain immune cells, including T cells. CTLA-4 is a negative regulator of T cell activation, meaning it helps to keep the immune response in check. However, in cancer, this protein is often overexpressed, leading to suppression of the immune response and allowing the tumor to grow unchecked. By binding to CTLA-4, Zalifrelimab Biosimilar blocks its activity and allows T cells to become activated and attack cancer cells. This leads to an enhanced immune response against the tumor, potentially slowing its growth and improving patient outcomes. Therapeutic Target of Zalifrelimab Biosimilar The therapeutic target of Zalifrelimab Biosimilar is CTLA-4, a protein that is involved in regulating the immune response. This protein is found on the surface of T cells and helps to prevent them from becoming overactive. However, in cancer, CTLA-4 is often overexpressed, leading to suppression of the immune response and allowing the tumor to grow. Zalifrelimab Biosimilar is designed to specifically target and bind to CTLA-4, blocking its activity and allowing T cells to become activated. This leads to an enhanced immune response against the tumor, potentially slowing its growth and improving patient outcomes. Potential Applications of Zalifrelimab Biosimilar Zalifrelimab Biosimilar has shown promise as a potential treatment for various types of cancer, including melanoma, non-small cell lung cancer, and renal cell carcinoma. It is currently being evaluated in clinical trials for these indications and has shown promising results in early studies. In addition to its potential as a monotherapy, Zalifrelimab Biosimilar is also being studied in combination with other cancer treatments, such as chemotherapy and other immunotherapies. This is because the combination of different treatments can often lead to a more effective and comprehensive attack on the tumor. Conclusion Zalifrelimab Biosimilar, also known as Anti-CTLA4 or CD152 monoclonal antibody, is a research grade therapeutic antibody designed to mimic the activity of the original antibody, Ipilimumab. It works by targeting CTLA-4, a protein found on the surface of T cells, and blocking its activity to enhance the immune response against cancer. This biosimilar has shown promise in clinical trials for various types of cancer and has the potential to improve patient outcomes. Further research and development of Zalifrelimab Biosimilar could lead to a new and

Zalifrelimab, Abbexa, abx831518

Zalifrelimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CTLA4/CD152, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Balstilimab monotherapy and combined with zalifrelimab in the treatment of metastatic cervical cancer.

Zalifrelimab ELISA Kit, ProteoGenix, KPTX197

Description of Zalifrelimab ELISA Kit The Structure of Zalifrelimab ELISA Kit Zalifrelimab ELISA Kit is a highly sensitive and specific diagnostic tool used in the detection and quantification of Zalifrelimab, a monoclonal antibody used as a therapeutic agent. The kit is composed of several components, including a microplate coated with a specific antibody, a detection antibody, and a colorimetric substrate. The structure of the kit allows for the precise and accurate measurement of Zalifrelimab levels in various biological samples. The microplate used in the kit is coated with a specific antibody that binds specifically to Zalifrelimab. This antibody is immobilized on the surface of the plate, ensuring that only Zalifrelimab present in the sample will be captured. The microplate is made of a high-quality plastic material that is resistant to chemical reactions, ensuring the stability of the kit components. The detection antibody used in the kit is a biotinylated monoclonal antibody that recognizes a different epitope on Zalifrelimab. This antibody is labeled with biotin, a vitamin B derivative that binds specifically to streptavidin, an enzyme used in the detection process. The detection antibody is added to the microplate after the sample has been incubated, allowing it to bind to any Zalifrelimab present in the sample. The Activity of Zalifrelimab ELISA Kit Zalifrelimab ELISA Kit utilizes the principle of enzyme-linked immunosorbent assay (ELISA) to detect and quantify Zalifrelimab levels in biological samples. The kit is based on the specific binding of Zalifrelimab to two different antibodies, one immobilized on the microplate and the other labeled with biotin. The activity of the kit involves several steps, including sample preparation, incubation, washing, and detection. The first step in the activity of the kit is the preparation of the sample, which involves the extraction and purification of Zalifrelimab from the biological sample. This step is crucial in ensuring the accuracy and reliability of the results. Once the sample is prepared, it is added to the microplate coated with the specific antibody. Zalifrelimab present in the sample binds to the immobilized antibody, while other components of the sample are washed away. After the incubation step, the microplate is washed to remove any unbound components. This step ensures the specificity of the assay by removing any non-specific binding. The detection antibody labeled with biotin is then added to the microplate, binding to the captured Zalifrelimab. Streptavidin is then added, which binds to the biotinylated detection antibody, forming an enzyme-antibody complex. The final step in the activity of the kit is the addition of a colorimetric substrate, which reacts with the enzyme to produce a color change. The intensity of the color is directly proportional to the amount of Zalifrelimab present in the sample. The microplate is then read using a spectrophotometer, and the results are calculated using a standard curve. The activity of the kit is highly sensitive and specific, allowing for the accurate detection and quantification of Zalifrelimab levels in various biological samples. Application of Zalifrelimab ELISA Kit Zalifrelimab ELISA Kit has a wide range of applications in both research and clinical settings. In research, the kit is used to study the pharmacokinetics and pharmacodynamics of Zalifrelimab, providing valuable insights into its mechanism of action and potential therapeutic benefits. The kit is also used to monitor Zalifrelimab levels in preclinical and clinical studies, aiding in the development and optimization of dosing regimens. In clinical settings, Zalifrelimab ELISA Kit is used for the diagnosis and monitoring of patients receiving Zalifrelimab therapy. The kit allows for the precise and accurate measurement of Zalif

Zalifrelimab ELISA Kit, Abbexa, abx395086

Zalifrelimab ELISA Kit is a quantitative ELISA kit for detection of Zalifrelimab.Zalifrelimab is a novel, fully human monoclonal immunoglobulin G1 (IgG1) designed to block CTLA-4 (cytotoxic T-lymphocyte associated antigen 4) from interacting with its ligands CD80 and CD86. CTLA-4 is a negative regulator of immune activation that is considered a foundational target within the immuno-oncology market.

Zalifrelimab Biosimilar - Research Grade, ichor.bio, ICH5998

Research Grade Zalifrelimab (HB651026), abinScience, HB651026